The first stage of testing of the experimental COVID-19 pill called Molnupiravir, by Merck and Ridgeback Biotherapeutics, has proved to be an effective way to fight the virus. The medication functions as an at-home, five-day treatment, similar to Tamiflu, that attacks the virus preventing it from spreading and causing major damage.
“This might be the future once the vaccine really gets control over the pandemic and we just start seeing isolated cases,” said Dr. Marc Siegel, professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center. “By then, this drug might be ready and this might be the drug for over the next several months.”
Siegel made a bold prediction on Fox & Friends that the U.S. will be free of the coronavirus pandemic by the summer. He continued to say that the Molnupiravir treatment will be “very helpful” for managing isolated cases.
“This is the very first pill that we have that’s something that we might be able to use in our armamentarium against COVID as a therapeutic,” he said.
Merck said that no side effects have been reported thus far and, “of the 4 serious adverse events reported, none were considered to be study-drug related.”
Stay in the know with Medicare World! Sign up for our weekly newsletter to keep up with the latest COVID-19 developments.